SELLAS Life Sciences Group, Inc.
SLS
$1.56
-$0.05-3.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -27.13M | -30.88M | -32.28M | -34.44M | -35.81M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.16M | 2.13M | 2.23M | 2.38M | 2.57M |
| Change in Net Operating Assets | -8.75M | -6.65M | -3.02M | -97.00K | 3.19M |
| Cash from Operations | -33.71M | -35.40M | -33.07M | -32.16M | -30.04M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 0.00 | -3.00M | -5.50M |
| Cash from Investing | -- | -- | 0.00 | -3.00M | -5.50M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 43.76M | 46.82M | 50.17M | 30.53M | 30.12M |
| Repurchase of Common Stock | -64.00K | -64.00K | -31.00K | -31.00K | -60.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 43.69M | 46.76M | 50.14M | 30.50M | 30.06M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.98M | 11.36M | 17.06M | -4.66M | -5.49M |